Study ties protein ‘reader’ ENL to common leukaemia

Google+ Pinterest LinkedIn Tumblr +

AML-M5AAnyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid leukaemia (AML), a fast-growing cancer of bone marrow and blood cells and the second most common type of leukaemia in children and adults.

Findings from a study at The University of Texas MD Anderson Cancer Center revealed the leukaemia-boosting abilities of ENL, which contains a protein component called YEATS that “reads” histone proteins.

Histone proteins make up chromatin, large clusters of DNA- and RNA-containing molecules comprising our body’s chromosomes.

Just as a scanner “reads” data on an identification badge, ENL recognises a type of histone modification known as acetylation.

Research results, which build upon a previous MD Anderson study of histone-reading proteins, are published in Nature.

The findings indicated treatment against ENL with a class of experimental drugs called bromodomain and extra-terminal (BET) inhibitors may be effective for treating AML.

“Our study showed that ENL is required for disease maintenance in AML,” said Xiaobing Shi, Ph.D., associate professor of Epigenetics and Molecular Carcinogenesis.

“Depletion of ENL led to anti-leukaemic effects, suppressing growth both in vivo and in vitro. Notably, disrupting ENL further sensitised leukaemia cells to BET inhibitors.”

Histone modifications like acetylation serve as docking sites for reader proteins which recognise specific modifications, influencing downstream biological outcomes.

While many such reader proteins have been identified for histone modifications called methylation, few are known to recognise histone acetylation.

Shi’s team employed CRISPR, a gene-editing tool, to deplete ENL and suppress cancer gene expression, which was crucial given that cancer cells often co-opt chromatin regulatory pathways.

“Targeting epigenetic readers represents a class of anti-cancer therapy that we believe holds clinical promise,” said Hong Wen, Ph.D., research assistant professor of Epigenetics and Molecular Carcinogenesis and co-first author of the paper. “Our study revealed ENL as a chromatin reader that regulates oncogenic programs, thus establishing ENL as a potential drug target for AML.”
[hr] Source: University Of Texas M. D. Anderson Cancer Center

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.